Bellevue Group AG boosted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 13.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 60,962 shares of the medical research company's stock after acquiring an additional 7,339 shares during the period. Bellevue Group AG's holdings in Thermo Fisher Scientific were worth $31,714,000 at the end of the most recent reporting period.
Other institutional investors have also added to or reduced their stakes in the company. Norges Bank bought a new position in Thermo Fisher Scientific in the fourth quarter worth $3,149,754,000. T. Rowe Price Investment Management Inc. increased its stake in shares of Thermo Fisher Scientific by 86.9% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,083,900 shares of the medical research company's stock worth $1,604,338,000 after acquiring an additional 1,433,444 shares in the last quarter. Kovitz Investment Group Partners LLC boosted its stake in Thermo Fisher Scientific by 1,905.4% during the fourth quarter. Kovitz Investment Group Partners LLC now owns 903,232 shares of the medical research company's stock worth $469,889,000 after acquiring an additional 858,193 shares in the last quarter. Proficio Capital Partners LLC increased its stake in shares of Thermo Fisher Scientific by 68,617.0% during the fourth quarter. Proficio Capital Partners LLC now owns 762,759 shares of the medical research company's stock valued at $396,810,000 after purchasing an additional 761,649 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth approximately $377,901,000. 89.23% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
Several analysts recently commented on TMO shares. Scotiabank cut their price objective on shares of Thermo Fisher Scientific from $650.00 to $605.00 and set a "sector perform" rating on the stock in a research report on Friday, April 25th. Sanford C. Bernstein upgraded Thermo Fisher Scientific from a "market perform" rating to an "outperform" rating and set a $630.00 target price on the stock in a research note on Friday, January 10th. Barclays dropped their price objective on Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 10th. StockNews.com cut shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a report on Friday, April 25th. Finally, UBS Group dropped their target price on shares of Thermo Fisher Scientific from $715.00 to $500.00 and set a "buy" rating on the stock in a report on Thursday, April 24th. Five investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat.com, Thermo Fisher Scientific presently has an average rating of "Moderate Buy" and an average price target of $607.43.
Read Our Latest Analysis on TMO
Insider Buying and Selling
In other news, SVP Michael A. Boxer sold 3,775 shares of the business's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the completion of the sale, the senior vice president now directly owns 10,816 shares of the company's stock, valued at approximately $5,759,736.32. The trade was a 25.87 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total transaction of $5,166,700.00. Following the completion of the transaction, the chief executive officer now directly owns 115,174 shares in the company, valued at $59,506,950.58. This represents a 7.99 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 14,075 shares of company stock valued at $7,305,942 in the last ninety days. 0.33% of the stock is owned by company insiders.
Thermo Fisher Scientific Price Performance
Shares of Thermo Fisher Scientific stock traded down $14.91 during trading hours on Tuesday, reaching $407.36. The company's stock had a trading volume of 3,874,201 shares, compared to its average volume of 1,784,510. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. Thermo Fisher Scientific Inc. has a one year low of $406.72 and a one year high of $627.88. The firm has a 50 day moving average price of $471.62 and a 200-day moving average price of $518.58. The stock has a market cap of $153.78 billion, a P/E ratio of 24.64, a P/E/G ratio of 2.99 and a beta of 0.82.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, topping analysts' consensus estimates of $5.10 by $0.05. The firm had revenue of $10.36 billion during the quarter, compared to analysts' expectations of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The company's quarterly revenue was up .2% on a year-over-year basis. During the same quarter in the previous year, the business earned $5.11 EPS. On average, analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.
Thermo Fisher Scientific Increases Dividend
The company also recently declared a quarterly dividend, which was paid on Tuesday, April 15th. Investors of record on Friday, March 14th were issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 0.42%. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.39. The ex-dividend date of this dividend was Friday, March 14th. Thermo Fisher Scientific's dividend payout ratio is presently 10.09%.
Thermo Fisher Scientific Profile
(
Free Report)
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Further Reading
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
